Small Phase II Study Examines Triplet Regimen for Patients With HER2-Positive Breast Cancer and Leptomeningeal Metastasis - Summary - MDSpire
From the Journals
Clinical Guidelines

Small Phase II Study Examines Triplet Regimen for Patients With HER2-Positive Breast Cancer and Leptomeningeal Metastasis

Results from a small phase II study suggest that a triplet regimen may improve symptoms and extend survival in some patients with breast cancer and leptomeningeal metastasis, who often face limited tr...

Share

Recent research led by Dr. Rashmi Murthy has identified a promising treatment for patients with leptomeningeal metastasis due to HER2-positive breast cancer. The phase II TBCRC049 study involved 17 female patients and indicated that the combination of tucatinib, trastuzumab, and capecitabine significantly improved median overall survival from 4.4 months to 10 months, with 41% of patients alive at 18 months. Notably, the treatment also resulted in improvements in neurologic symptoms, addressing a critical need in this challenging clinical setting.

Original Source(s)

Small Phase II Study Examines Triplet Regimen for Patients With HER2-Positive Breast Cancer and Leptomeningeal Metastasis

  • by The ASCO Post Staff

  • April 8, 2026

Related Content

Antibody Oxidation’s Hidden Handedness Comes Into View

Integrated NMR and LC-MS analysis distinguishes elusive stereochemical forms of methionine oxidation in IgG1 Fc regions, offering a sharper tool for biologic drug quality control

  • April 8, 2026

  • 2 min
Analysis Shows Nearly 7% of Global Clinical Trials Are Impacted by Middle East Disruption

Oncology trials account for a substantial proportion of impacted activity, with non–small cell lung cancer representing the most affected indication, followed by breast cancer.

Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer

As reported in The New England Journal of Medicine by Vulsteke et al, the phase III KEYNOTE-905/EV-303 trial has shown improved event-free and overall survival with the addition of perioperative enfor...